FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for high-risk early-stage triple-negative breast cancer
0:00
4:00
Listen to a soundcast of the July 26, 2021 FDA approval of Keytruda (pembrolizumab) for high-risk early-stage triple-negative breast cancer
Flere episoder fra "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Gå ikke glip af nogen episoder af “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” - abonnér på podcasten med gratisapp GetPodcast.